130 related articles for article (PubMed ID: 36657246)
1. Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world.
Rozema J; Graafsma J; Hoogendoorn M; Kibbelaar R; Veeger N; van Roon E;
J Geriatr Oncol; 2023 Mar; 14(2):101418. PubMed ID: 36657246
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
[TBL] [Abstract][Full Text] [Related]
3. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.
Zeidan AM; Klink AJ; McGuire M; Feinberg B
Leuk Lymphoma; 2019 Aug; 60(8):2050-2055. PubMed ID: 30636526
[TBL] [Abstract][Full Text] [Related]
4. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
Bello C; Yu D; Komrokji RS; Zhu W; Wetzstein GA; List AF; Lancet JE
Cancer; 2011 Apr; 117(7):1463-9. PubMed ID: 21425147
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices.
Egloff SA; Cao X; Lachs R; Martin C; Mattlin M; Fennell E; Rayburn D; Schlauch D; Kurbegov D; Ide S; Battiwalla M
Leuk Lymphoma; 2023 Dec; 64(13):2101-2112. PubMed ID: 37680012
[TBL] [Abstract][Full Text] [Related]
8. Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study.
Rozema J; Hoogendoorn M; Kibbelaar R; van den Berg E; Veeger N; van Roon E
Blood Adv; 2021 Mar; 5(5):1344-1351. PubMed ID: 33656535
[TBL] [Abstract][Full Text] [Related]
9. The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.
Cogle CR; Kurtin SE; Bentley TG; Broder MS; Chang E; Megaffin S; Fruchtman S; Petrone ME; Mukherjee S
Oncologist; 2017 Apr; 22(4):379-385. PubMed ID: 28283585
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience.
Grabska J; Shah B; Reed D; Al Ali N; Padron E; Ramadan H; Lancet J; List A; Komrokji R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S53-6. PubMed ID: 27521325
[TBL] [Abstract][Full Text] [Related]
11. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
Zeidan AM; Gore SD; McNally DL; Baer MR; Hendrick F; Mahmoud D; Davidoff AJ
Cancer; 2013 Nov; 119(21):3870-8. PubMed ID: 23922173
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
14. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.
Dinmohamed AG; Visser O; van Norden Y; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Eur J Cancer; 2014 Mar; 50(5):1004-12. PubMed ID: 24388662
[TBL] [Abstract][Full Text] [Related]
15. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Clavio M; Crisà E; Miglino M; Guolo F; Ceccarelli M; Salvi F; Allione B; Ferrero D; Balleari E; Finelli C; Poloni A; Selleri C; Danise P; Cilloni D; Di Tucci AA; Cametti G; Freilone R; Fanin R; Bigazzi C; Zambello R; Crugnola M; Oliva EN; Centurioni R; Alesiani F; Catarini M; Castelli A; Abbadessa A; Capalbo SF; Musto P; Angelucci E; Santini V
Cancer; 2021 Jun; 127(12):2015-2024. PubMed ID: 33739457
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure.
Swaminathan M; Borthakur G; Kadia TM; Ferrajoli A; Alvarado Y; Pemmaraju N; Bodden K; Yearby B; Konopleva M; Khoury J; Bueso-Ramos C; Garcia-Manero G; DiNardo CD
Leuk Lymphoma; 2019 Sep; 60(9):2207-2213. PubMed ID: 30773968
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
[TBL] [Abstract][Full Text] [Related]
19. How we manage adults with myelodysplastic syndrome.
Fenaux P; Platzbecker U; Ades L
Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
[TBL] [Abstract][Full Text] [Related]
20. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents.
Zeidan AM; Hu X; Zhu W; Stahl M; Wang R; Huntington SF; Giri S; Bewersdorf JP; Podoltsev NA; Gore SD; Ma X; Davidoff AJ
Leuk Lymphoma; 2020 Feb; 61(2):397-408. PubMed ID: 31570040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
